paper_id,paper_title,source_type,stress_type,detected_text,near_temp,near_time,near_rh,near_lux,near_uv,raw_text_snippet
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,acid_hydrolysis,2MHCl,,72h,,,200Wh/m2,ddegradationstudies. API:Year Acid Base Neutral Thermolysis Oxidation Photolysis Zidovudine: Acid/baseat80 ◦ C 10%H O atroom 1.2×106lx×hoffluorescent 2MHCl 2MNaOH - 2 2 lightand200Wh/m2UV 2017[65] for72h temperaturefor10h light To 20 lo 1 x 8 a [ t 6 o 6 n ] e: 1MHCl 0.01MNaOH H 2 O Allh ◦ y C dr f o o l r y 2 sis h at80 0 t . e 0 m 1% pe H ra 2 t O ur 2 e a f t o r r o 2 om h 2700kJ U /m V 2 C /h
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,acid_hydrolysis,1MHCl,,72h,,,200Wh/m2,0%H O atroom 1.2×106lx×hoffluorescent 2MHCl 2MNaOH - 2 2 lightand200Wh/m2UV 2017[65] for72h temperaturefor10h light To 20 lo 1 x 8 a [ t 6 o 6 n ] e: 1MHCl 0.01MNaOH H 2 O Allh ◦ y C dr f o o l r y 2 sis h at80 0 t . e 0 m 1% pe H ra 2 t O ur 2 e a f t o r r o 2 om h 2700kJ U /m V 2 C /h 7. o 5 f W UV /m -V 2 ISand ◦ ◦ 1.2×106lx×hoffluorescent Am 20 l 1 o 5 d [ i 6 p 7 in ] e: 1M fo H r C 3 l 0 a 
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,acid_hydrolysis,1MHCl,,14day,,,200Wh/m2,m 5% pe H ra 2 t O u 2 re a f t o r r o 4 o 8 m h lightand200Wh/m2UV-A lightfor14days Notlessthan1.2×106lx×h Acebutolol: Allhydrolysisat80 ◦ 2018[68] 1MHCl 2MHCl H 2 O ◦ C 3%H 2 O 2 at80 C andultravioletenergyofnot lessthan200Wh/m2 Stevioside: 0.1MHCl/0.1M Allhydrolysisat80 ◦ 2018[69] H PO 0.1MNaOH H 2 O ◦ Cfor8h 10%H 2 O 2 at25 Cfor72h UV 254nm lampfor48h 3 4 ◦ ◦ Pentoxifylline: 2MHClat70 C 2MNaO
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,acid_hydrolysis,2MHCl,,14day,,,200Wh/m2,e H ra 2 t O u 2 re a f t o r r o 4 o 8 m h lightand200Wh/m2UV-A lightfor14days Notlessthan1.2×106lx×h Acebutolol: Allhydrolysisat80 ◦ 2018[68] 1MHCl 2MHCl H 2 O ◦ C 3%H 2 O 2 at80 C andultravioletenergyofnot lessthan200Wh/m2 Stevioside: 0.1MHCl/0.1M Allhydrolysisat80 ◦ 2018[69] H PO 0.1MNaOH H 2 O ◦ Cfor8h 10%H 2 O 2 at25 Cfor72h UV 254nm lampfor48h 3 4 ◦ ◦ Pentoxifylline: 2MHClat70 C 2MNaOHat70 
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,acid_hydrolysis,0.1MHCl,,8h,,,200Wh/m2,han1.2×106lx×h Acebutolol: Allhydrolysisat80 ◦ 2018[68] 1MHCl 2MHCl H 2 O ◦ C 3%H 2 O 2 at80 C andultravioletenergyofnot lessthan200Wh/m2 Stevioside: 0.1MHCl/0.1M Allhydrolysisat80 ◦ 2018[69] H PO 0.1MNaOH H 2 O ◦ Cfor8h 10%H 2 O 2 at25 Cfor72h UV 254nm lampfor48h 3 4 ◦ ◦ Pentoxifylline: 2MHClat70 C 2MNaOHat70 C ◦ Dryheatunderat ◦ 2013[70] for4h for4h H 2 Oat70 Cfor4h 105 ◦ Cfor4h 30%H 2 O 2 at70 
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,acid_hydrolysis,2MHCl,,8h,,,,tevioside: 0.1MHCl/0.1M Allhydrolysisat80 ◦ 2018[69] H PO 0.1MNaOH H 2 O ◦ Cfor8h 10%H 2 O 2 at25 Cfor72h UV 254nm lampfor48h 3 4 ◦ ◦ Pentoxifylline: 2MHClat70 C 2MNaOHat70 C ◦ Dryheatunderat ◦ 2013[70] for4h for4h H 2 Oat70 Cfor4h 105 ◦ Cfor4h 30%H 2 O 2 at70 Cfor4h Sunlightfor8h ◦ Le 2 fl 0 u 1 n 5 o [ m 71 i ] de: 0.1–5 f M or8 at h 85 C 0.1M ◦ C N f a o O r8 H h at85 H 2 Oat85 ◦ Cfor8h 50 ◦ Cf
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,acid_hydrolysis,0.1MHCl,,85 H,,,, H h at85 H 2 Oat85 ◦ Cfor8h 50 ◦ Cfor30days te 3 m 0% pe H ra 2 t O u 2 re a f t o r r o 2 o 4 m h UVand 1 w 4 h d i a t y e s lightfor ◦ ◦ Actarit: 0.1MHClat70 0.1MNaOHat70 H Oat70 Cfor14 Dryheatat70 C 2014[72] ◦ Cfor24h ◦ Cfor24h 2 days for14days 3%H 2 O 2 for14days UVlight ◦ ◦ Nicardipine: 1MHClat60 C 0.1–0.5MNaOHat 5%H O at30–50 Cfor1 UV lightatroom ◦ - - 2 2 254–365nm 2014[73] for1h 50–80 Cf
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,acid_hydrolysis,1MHCl,,70 H,,,,rit: 0.1MHClat70 0.1MNaOHat70 H Oat70 Cfor14 Dryheatat70 C 2014[72] ◦ Cfor24h ◦ Cfor24h 2 days for14days 3%H 2 O 2 for14days UVlight ◦ ◦ Nicardipine: 1MHClat60 C 0.1–0.5MNaOHat 5%H O at30–50 Cfor1 UV lightatroom ◦ - - 2 2 254–365nm 2014[73] for1h 50–80 Cfor1h h temperature Clopidogrel Allhydrolysisat80 bisulfate: 1MHCl 1MNaOH - ◦ Cfor1h 5%H 2 O 2 - 2010[74] Fromroom Biapenem: ◦ pHfrom2.5to7.5at80 
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,acid_hydrolysis,1MHCl,,1h,,,,–0.5MNaOHat 5%H O at30–50 Cfor1 UV lightatroom ◦ - - 2 2 254–365nm 2014[73] for1h 50–80 Cfor1h h temperature Clopidogrel Allhydrolysisat80 bisulfate: 1MHCl 1MNaOH - ◦ Cfor1h 5%H 2 O 2 - 2010[74] Fromroom Biapenem: ◦ pHfrom2.5to7.5at80 Cfor40min temperatureto100 - - 2009[75] ◦ CinpH3.5 ◦ ◦ ◦ Ir 2 b 0 e 1 s 0 a [ r 7 ta 6 n ] : 1MH fo C r l 2 a 4 t h 80 C 2MN f a o O r H 48 a h t80 C H 2 Oa 4 t 8 80
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,base_hydrolysis,2MNaOH,,72h,,,200Wh/m2,dationstudies. API:Year Acid Base Neutral Thermolysis Oxidation Photolysis Zidovudine: Acid/baseat80 ◦ C 10%H O atroom 1.2×106lx×hoffluorescent 2MHCl 2MNaOH - 2 2 lightand200Wh/m2UV 2017[65] for72h temperaturefor10h light To 20 lo 1 x 8 a [ t 6 o 6 n ] e: 1MHCl 0.01MNaOH H 2 O Allh ◦ y C dr f o o l r y 2 sis h at80 0 t . e 0 m 1% pe H ra 2 t O ur 2 e a f t o r r o 2 om h 2700kJ U /m V 2 C /h 7. o 
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,base_hydrolysis,0.01MNaOH,,72h,,,200Wh/m2,atroom 1.2×106lx×hoffluorescent 2MHCl 2MNaOH - 2 2 lightand200Wh/m2UV 2017[65] for72h temperaturefor10h light To 20 lo 1 x 8 a [ t 6 o 6 n ] e: 1MHCl 0.01MNaOH H 2 O Allh ◦ y C dr f o o l r y 2 sis h at80 0 t . e 0 m 1% pe H ra 2 t O ur 2 e a f t o r r o 2 om h 2700kJ U /m V 2 C /h 7. o 5 f W UV /m -V 2 ISand ◦ ◦ 1.2×106lx×hoffluorescent Am 20 l 1 o 5 d [ i 6 p 7 in ] e: 1M fo H r C 3 l 0 a m t8 i
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,base_hydrolysis,0.1MNaOH,,8h,,,200Wh/m2,2018[68] 1MHCl 2MHCl H 2 O ◦ C 3%H 2 O 2 at80 C andultravioletenergyofnot lessthan200Wh/m2 Stevioside: 0.1MHCl/0.1M Allhydrolysisat80 ◦ 2018[69] H PO 0.1MNaOH H 2 O ◦ Cfor8h 10%H 2 O 2 at25 Cfor72h UV 254nm lampfor48h 3 4 ◦ ◦ Pentoxifylline: 2MHClat70 C 2MNaOHat70 C ◦ Dryheatunderat ◦ 2013[70] for4h for4h H 2 Oat70 Cfor4h 105 ◦ Cfor4h 30%H 2 O 2 at70 Cfor4h Sunlightfor8h ◦ Le 2 fl 0 u 1 n 5 o [ m 
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,base_hydrolysis,2MNaOH,,8h,,,,.1MHCl/0.1M Allhydrolysisat80 ◦ 2018[69] H PO 0.1MNaOH H 2 O ◦ Cfor8h 10%H 2 O 2 at25 Cfor72h UV 254nm lampfor48h 3 4 ◦ ◦ Pentoxifylline: 2MHClat70 C 2MNaOHat70 C ◦ Dryheatunderat ◦ 2013[70] for4h for4h H 2 Oat70 Cfor4h 105 ◦ Cfor4h 30%H 2 O 2 at70 Cfor4h Sunlightfor8h ◦ Le 2 fl 0 u 1 n 5 o [ m 71 i ] de: 0.1–5 f M or8 at h 85 C 0.1M ◦ C N f a o O r8 H h at85 H 2 Oat85 ◦ Cfor8h 50 ◦ Cfor30days te 
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,base_hydrolysis,0.1MNaOH,,8h,,,,2 Oat85 ◦ Cfor8h 50 ◦ Cfor30days te 3 m 0% pe H ra 2 t O u 2 re a f t o r r o 2 o 4 m h UVand 1 w 4 h d i a t y e s lightfor ◦ ◦ Actarit: 0.1MHClat70 0.1MNaOHat70 H Oat70 Cfor14 Dryheatat70 C 2014[72] ◦ Cfor24h ◦ Cfor24h 2 days for14days 3%H 2 O 2 for14days UVlight ◦ ◦ Nicardipine: 1MHClat60 C 0.1–0.5MNaOHat 5%H O at30–50 Cfor1 UV lightatroom ◦ - - 2 2 254–365nm 2014[73] for1h 50–80 Cfor1h h tempe
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,base_hydrolysis,0.5MNaOH,,70 H,,,, 0.1MNaOHat70 H Oat70 Cfor14 Dryheatat70 C 2014[72] ◦ Cfor24h ◦ Cfor24h 2 days for14days 3%H 2 O 2 for14days UVlight ◦ ◦ Nicardipine: 1MHClat60 C 0.1–0.5MNaOHat 5%H O at30–50 Cfor1 UV lightatroom ◦ - - 2 2 254–365nm 2014[73] for1h 50–80 Cfor1h h temperature Clopidogrel Allhydrolysisat80 bisulfate: 1MHCl 1MNaOH - ◦ Cfor1h 5%H 2 O 2 - 2010[74] Fromroom Biapenem: ◦ pHfrom2.5to7.5at80 Cfor40min temper
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,base_hydrolysis,1MNaOH,,1h,,,,aOHat 5%H O at30–50 Cfor1 UV lightatroom ◦ - - 2 2 254–365nm 2014[73] for1h 50–80 Cfor1h h temperature Clopidogrel Allhydrolysisat80 bisulfate: 1MHCl 1MNaOH - ◦ Cfor1h 5%H 2 O 2 - 2010[74] Fromroom Biapenem: ◦ pHfrom2.5to7.5at80 Cfor40min temperatureto100 - - 2009[75] ◦ CinpH3.5 ◦ ◦ ◦ Ir 2 b 0 e 1 s 0 a [ r 7 ta 6 n ] : 1MH fo C r l 2 a 4 t h 80 C 2MN f a o O r H 48 a h t80 C H 2 Oa 4 t 8 80 h Cfo
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,photolysis,200Wh/m2,,72h,,,200Wh/m2,ar Acid Base Neutral Thermolysis Oxidation Photolysis Zidovudine: Acid/baseat80 ◦ C 10%H O atroom 1.2×106lx×hoffluorescent 2MHCl 2MNaOH - 2 2 lightand200Wh/m2UV 2017[65] for72h temperaturefor10h light To 20 lo 1 x 8 a [ t 6 o 6 n ] e: 1MHCl 0.01MNaOH H 2 O Allh ◦ y C dr f o o l r y 2 sis h at80 0 t . e 0 m 1% pe H ra 2 t O ur 2 e a f t o r r o 2 om h 2700kJ U /m V 2 C /h 7. o 5 f W UV /m -V 2 ISan
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,photolysis,200Wh/m2,,2h,,,200Wh/m2,fo H r C 3 l 0 a m t8 in 0 C 1MNa fo O r H 1 a h t80 C H 2 Oat80 ◦ Cfor2h 50 ◦ Cfor48h te 1 m 5% pe H ra 2 t O u 2 re a f t o r r o 4 o 8 m h lightand200Wh/m2UV-A lightfor14days Notlessthan1.2×106lx×h Acebutolol: Allhydrolysisat80 ◦ 2018[68] 1MHCl 2MHCl H 2 O ◦ C 3%H 2 O 2 at80 C andultravioletenergyofnot lessthan200Wh/m2 Stevioside: 0.1MHCl/0.1M Allhydrolysisat80 ◦ 2018[69] H PO 0.1MNaOH H 2 O ◦ 
Chemometrics Approaches in Forced Degradation,Chemometrics Approaches in Forced Degradation,TEXT,photolysis,200Wh/m2,,14day,,,200Wh/m2,ghtfor14days Notlessthan1.2×106lx×h Acebutolol: Allhydrolysisat80 ◦ 2018[68] 1MHCl 2MHCl H 2 O ◦ C 3%H 2 O 2 at80 C andultravioletenergyofnot lessthan200Wh/m2 Stevioside: 0.1MHCl/0.1M Allhydrolysisat80 ◦ 2018[69] H PO 0.1MNaOH H 2 O ◦ Cfor8h 10%H 2 O 2 at25 Cfor72h UV 254nm lampfor48h 3 4 ◦ ◦ Pentoxifylline: 2MHClat70 C 2MNaOHat70 C ◦ Dryheatunderat ◦ 2013[70] for4h for4h H 2 Oat70 Cfor4h 105 ◦ Cf
Paper-1,Paper-1,TEXT,humidity,75% relative humidity,10°C,,75% relative humidity,,,"stance. The testing should include the effect of temperatures (in 10°C increments (ie, 50°C, 60°C) above that for accelerated testing), humidity (ie, 75% relative humidity or greater) where appropriate, oxidation, and photolysis on the drug substance. The testing should also evaluate the susceptibility of the drug substance to hydrolysis across a wide range of pH values when in solution or suspens"
Paper-1,Paper-1,TEXT,thermal,10°C,10°C,,75% relative humidity,,,"tates: “Stress testing is likely to be carried out on a single batch of the drug substance. The testing should include the effect of temperatures (in 10°C increments (ie, 50°C, 60°C) above that for accelerated testing), humidity (ie, 75% relative humidity or greater) where appropriate, oxidation, and photolysis on the drug substance. The testing should also evaluate the susceptibility of the drug "
Paper-1,Paper-1,TEXT,thermal,50°C,10°C,,75% relative humidity,,,"g is likely to be carried out on a single batch of the drug substance. The testing should include the effect of temperatures (in 10°C increments (ie, 50°C, 60°C) above that for accelerated testing), humidity (ie, 75% relative humidity or greater) where appropriate, oxidation, and photolysis on the drug substance. The testing should also evaluate the susceptibility of the drug substance to hydrolys"
Paper-1,Paper-1,TEXT,thermal,60°C,10°C,,75% relative humidity,,,"ikely to be carried out on a single batch of the drug substance. The testing should include the effect of temperatures (in 10°C increments (ie, 50°C, 60°C) above that for accelerated testing), humidity (ie, 75% relative humidity or greater) where appropriate, oxidation, and photolysis on the drug substance. The testing should also evaluate the susceptibility of the drug substance to hydrolysis acr"
Paper-1,Paper-1,TEXT,acid_hydrolysis,0.5N HCl,80°C,,,,,"e conditions (80°C or These one-time stress studies on a single batch are optimization of stress conditions.5Such a proactive even higher, 0.5N NaOH, 0.5N HCl, 3% H O ) 2 2 5 oN 01 loV 0102 enuJ ygolonhceT yrevileD gurD TABLE 1 Conditions generally employed for forced degradation. XX"
Paper-1,Paper-1,TEXT,base_hydrolysis,0.5N NaOH,80°C,,,,,"n at extreme conditions (80°C or These one-time stress studies on a single batch are optimization of stress conditions.5Such a proactive even higher, 0.5N NaOH, 0.5N HCl, 3% H O ) 2 2 5 oN 01 loV 0102 enuJ ygolonhceT yrevileD gurD TABLE 1 Conditions generally employed for forced degradation. XX"
Paper-1,Paper-1,TEXT,humidity,60% RH,25°C,,60% RH,,," degradation studies could be delayed as late as conditions than those used for accelerated studies Phase III clinical trials of the regulatory (25°C/60% RH or 40°C/75% RH) should be used. submission process. However, given the predictive At a minimum, the following conditions should be APPROPRIATE TIMING nature of forced degradation studies, these studies investigated: (1) acid and base hydrolysi"
Paper-1,Paper-1,TEXT,humidity,75% RH,25°C,,60% RH,,,"udies could be delayed as late as conditions than those used for accelerated studies Phase III clinical trials of the regulatory (25°C/60% RH or 40°C/75% RH) should be used. submission process. However, given the predictive At a minimum, the following conditions should be APPROPRIATE TIMING nature of forced degradation studies, these studies investigated: (1) acid and base hydrolysis, (2) are most"
Paper-1,Paper-1,TEXT,thermal,40°C,40°C,,,,," an evaluation should be made to verify if the drug substance has been exposed to energy in excess of the energy provided by accelerated storage (ie, 40°C for 6 months). If the answer is yes, then the experiment can be stopped and a note of the stability of the drug substance can be made. Unduly overstressing the drug substance may produce aberrant results. judgment of the pharmaceutical researche"
Paper-1,Paper-1,TEXT,thermal,25°C,25°C,,60% RH,,,"ties. degradation studies could be delayed as late as conditions than those used for accelerated studies Phase III clinical trials of the regulatory (25°C/60% RH or 40°C/75% RH) should be used. submission process. However, given the predictive At a minimum, the following conditions should be APPROPRIATE TIMING nature of forced degradation studies, these studies investigated: (1) acid and base hydr"
Paper-1,Paper-1,TEXT,thermal,40°C,25°C,,60% RH,,,"on studies could be delayed as late as conditions than those used for accelerated studies Phase III clinical trials of the regulatory (25°C/60% RH or 40°C/75% RH) should be used. submission process. However, given the predictive At a minimum, the following conditions should be APPROPRIATE TIMING nature of forced degradation studies, these studies investigated: (1) acid and base hydrolysis, (2) are"
Paper-1,Paper-1,TEXT,thermal,80°C,80°C,,,,,"cientists have found it at elevated temperatures and humidity levels. degradation pathways elucidation, and practical to begin at extreme conditions (80°C or These one-time stress studies on a single batch are optimization of stress conditions.5Such a proactive even higher, 0.5N NaOH, 0.5N HCl, 3% H O ) 2 2 5 oN 01 loV 0102 enuJ ygolonhceT yrevileD gurD TABLE 1 Conditions generally employed for fo"
Paper-1,Paper-1,TEXT,thermal,25°C,25°C,48 h,,,," scientist should ensure the respectively. Therefore, the conditions for stress conditions are consistent with product chromatogram 3 (3% peroxide at 25°C, for 48 hrs) decomposition under normal manufacturing, were deemed suitable and were used for further storage, and intended use conditions. method optimization. Recommended stress factors include high and low For oxidative degradation with H O ,"
Paper-10,Paper-10,TEXT,photolysis,1.2 million lux,,,,1.2 million lux,,hoto radiation in the present study. Gamma irradiation was carried out at varying doses from 25 Gy to 800 Gy and photo irradiation was conducted over 1.2 million lux hours as per ICH Q1(B) guideline. The chemical stability of the exposed samples was analyzed using RP-HPLC analysis. Cipro oxacin and Promethazine aqueous API solution and formulations exhibited dose- dependent degradation on gamma ex
Paper-10,Paper-10,TEXT,photolysis,1.2 million lux,,,,1.2 million lux,,"ine of ICH Q1(B) addresses conditions to perform photostability testing14. As per the guideline, photostability is evaluated by exposing medicines to 1.2 million lux hours of visible light and not less than 200-watt hours/square meter near ultraviolet and cool white  uorescent and near ultraviolet lamps used as radiation sources. Space environment factors Page 3/23"
Paper-10,Paper-10,TEXT,humidity,45% relative humidity,,,45% relative humidity,,," both drugs API in liquid and solid-state and formulations, were stored in glass bottles and wrapped in aluminum foil in a stability chamber at 25 ºC/45% relative humidity (RH) for storage. Aqueous API solutions of CIP (100 ppm and 3000 ppm), solid CIP (100mg powder), aqueous API solutions of PMZ (100 ppm and 2500 ppm) and solid PMZ (100mg powder) were used for the radiation exposure study. All pr"
Paper-10,Paper-10,TEXT,photolysis,1.2 million lux,,,,1.2 million lux,,in an uncovered quartz crucible placed inside the photostability chamber. The samples underwent simultaneous exposure to 200 W*hr/m2 UV radiation and 1.2 million lux hours of visible radiation. All samples were exposed in duplicate sets to both photolytic and gamma radiation. All Control and exposed samples were stored in the refrigerator until HPLC analysis. Page 5/23
Paper-10,Paper-10,TEXT,photolysis,1.2 lux,,,,1.2 lux,,"Table 2 Degradation summery of CIP irradiated by Photo and Gamma radiation. Sample Radiation/dose %Degradation Degradation Products RRT 100ppm (1.2 lux M.hr/ 200- 25.87% 0.39(CIP3), 0.44(CIP4), 0.51(CIP5), watt hours /square 0.59(CIP6), 0.68(CIP7), 0.78(CIP8) meter) 3000ppm 2.10% 0.39(CIP3), 0.44(CIP4), 0.51(CIP5), 0.68(CIP7) Formulation 1 2.50% 0.39(CIP3), 0.44(CIP4), 0.68(CIP7) without pac"
Paper-10,Paper-10,PDFPLUMBER_TABLE,photolysis,1.2 lux,,,,1.2 lux,,"Sample Radiation/dose %Degradation Degradation Products RRT 100ppm (1.2 lux M.hr/ 200- 25.87% 0.39(CIP3), 0.44(CIP4), 0.51(CIP5), watt hours /square 0.59(CIP6), 0.68(CIP7), 0.78(CIP8) meter) 3000ppm 2.10% 0.39(CIP3), 0.44(CIP4), 0.51(CIP5), 0.68(CIP7) Formulation 1 2.50% 0.39(CIP3), 0.44(CIP4), 0.68(CIP7) without pac"
Paper-10,Paper-10,CAMELOT_TABLE,photolysis,1.2 million lux,,,,1.2 million lux,,hoto radiation in the present study. Gamma irradiation was carried out at varying doses from 25 Gy to 800 Gy and photo irradiation was conducted over 1.2 million lux hours as per ICH Q1(B) guideline. The chemical stability of the exposed samples was analyzed using RP-HPLC analysis. Cipro oxacin and Promethazine aqueous API solution and formulations exhibited dose- dependent degradation on gamma ex
Paper-10,Paper-10,CAMELOT_TABLE,photolysis,1.2 million lux,,,,1.2 million lux,,"ine of ICH Q1(B) addresses conditions to perform photostability testing14. As per the guideline, photostability is evaluated by exposing medicines to 1.2 million lux hours of visible light and not less than 200-watt hours/square meter near ultraviolet and cool white  uorescent and near ultraviolet lamps used as radiation sources. Space environment factors"
Paper-11,Paper-11,TEXT,acid_hydrolysis,0.1 M HCl,,7 day,,,," degradation was performed using a water bath (Isotemp) purchased from Fisher Scientific. Acidic hydrolysis was performed at a final concentration of 0.1 M HCl, and oxidation was performed using a final concentration of AIBN at 5.7 mg/mL. All samples and controls were heated at 40◦C in a water bath. At 1, 3, 5 and 7 days, a 2 mL aliquot of the samples and controls was removed and either diluted (o"
Paper-11,Paper-11,TEXT,acid_hydrolysis,0.1N HCl,,2 day,,,," to be susceptible to reaction at the carboxamide link- age and the sulfonylurea bridge. To assess this reactivity, the drug substance was exposed to 0.1N HCl for acidic stability testing and AIBN for oxidative stability testing. The goal was to achieve 10–20% degradation as quantified by UV. The samples were tested at 2 day intervals and analyzed by UV-ELS and MS detection techniques. The drug su"
Paper-11,Paper-11,CAMELOT_TABLE,acid_hydrolysis,0.1 M HCl,,,,,,"hased from Fisher Scientiﬁc. Acidic the related com- working standards containing glimepiride and hydrolysis was performed at a ﬁnal concentration of 0.1 M HCl, pounds were analyzed on a UV-ELS system, connected in series. The and oxidation was performed using a ﬁnal concentration of AIBN calibration standards were prepared in triplicate at 10% (w/w), 20%, in a at 5.7 mg/mL. All samples and contro"
Paper-11,Paper-11,CAMELOT_TABLE,acid_hydrolysis,0.1N HCl,,,,,,"lfonylurea bridge. To assess this reactivity, the drug for response differences. Since both related impurities in this study substance was exposed to 0.1N HCl for acidic stability testing and have a RRF > 1.0, corrected areas were less than the (uncorrected) AIBN for oxidative stability testing. The goal was to achieve 10–20% peak area for each impurity. degradation as quantiﬁed by UV. The samples"
Paper-12,Paper-12,TEXT,acid_hydrolysis,1 N HCl,110 °C,3 h,,,,"ir Center for validated according to ICH Q2 (R2) guidelines, and forced degradation studies were Advance Research, BMU, Vesu, conducted under acidic (1 N HCl), alkaline (1 N NaOH), oxidative (3% H₂O₂), thermal Bharthana, Surat 395007, Gujarat, (110 °C for 3 h), and photolytic (UV light exposure) conditions. India Results Efonidipine and Metoprolol eluted at 7.17 and 2.77 min, respectively, showing"
Paper-12,Paper-12,TEXT,base_hydrolysis,1 N NaOH,110 °C,3 h,,,,"ted according to ICH Q2 (R2) guidelines, and forced degradation studies were Advance Research, BMU, Vesu, conducted under acidic (1 N HCl), alkaline (1 N NaOH), oxidative (3% H₂O₂), thermal Bharthana, Surat 395007, Gujarat, (110 °C for 3 h), and photolytic (UV light exposure) conditions. India Results Efonidipine and Metoprolol eluted at 7.17 and 2.77 min, respectively, showing good linearity for "
Paper-12,Paper-12,TEXT,thermal,110 °C,110 °C,3 h,,,,"e Advance Research, BMU, Vesu, conducted under acidic (1 N HCl), alkaline (1 N NaOH), oxidative (3% H₂O₂), thermal Bharthana, Surat 395007, Gujarat, (110 °C for 3 h), and photolytic (UV light exposure) conditions. India Results Efonidipine and Metoprolol eluted at 7.17 and 2.77 min, respectively, showing good linearity for EFO (20–120 µg/mL, r² = 0.9981) and MET (12.5–75 µg/mL, r² = 0.9961), high "
Paper-12,Paper-12,TEXT,thermal,110 °C,110 °C,3 h,,,,"² = 0.9981); MET: 12.5–75 µg/mL (r² = 0.9961) Degradation Oxidation, hydrolysis, photolysis, thermal Acidic, alkaline, oxidative, thermal Conditions (110 °C/3 h), photolytic (UV light) Results Good linearity (r² = 0.999), stability under High recovery (98–102%), stability stress not specified under thermal and photolytic condi- tions; degradation in acidic/alkaline Validation According to ICH guid"
Paper-12,Paper-12,TEXT,thermal,2 °C,2 °C,48 h,,,,"ibration curves. The stability of both standard and sample solutions of EFO and MET was assessed under two storage conditions: room temperature (25 ± 2 °C). Aliquots were withdrawn at 0 and 48 h and analysed using the validated RP-HPLC method. 2.7 Analysis of marketed formulation After calculating the average weight of twenty tablets, they were crushed into a fine powder. A 100 mL flask was filled"
Paper-12,Paper-12,TEXT,acid_hydrolysis,1 N HCl,60 °C,,,,,"e the inherent stability characteristics of the compounds. 2.9 Preparation of stock (1) Acid degradation The mixture was hydrolyzed by adding 5 mL of 1 N HCl, refluxed for an hour at 60 °C, cooled at room temperature, and neutralized with 1 N NaOH. (2) Alkaline degradation The mixture was hydrolyzed by adding 5 mL of 1 N NaOH, refluxed for an hour at 60 °C, cooled at room temperature, and neutrali"
Paper-12,Paper-12,TEXT,acid_hydrolysis,1 N HCl,60 °C,60 min,,,,"ne degradation The mixture was hydrolyzed by adding 5 mL of 1 N NaOH, refluxed for an hour at 60 °C, cooled at room temperature, and neutralized with 1 N HCl. (3) Oxidative Stress Oxidative degradation was conducted by treating both drugs with 5 mL of 3% hydrogen peroxide and refluxing the solution at 60 °C for 60 min. (4) Thermal degradation The process was performed by subjecting both drugs to a"
Paper-12,Paper-12,TEXT,base_hydrolysis,1 N NaOH,60 °C,,,,,"cid degradation The mixture was hydrolyzed by adding 5 mL of 1 N HCl, refluxed for an hour at 60 °C, cooled at room temperature, and neutralized with 1 N NaOH. (2) Alkaline degradation The mixture was hydrolyzed by adding 5 mL of 1 N NaOH, refluxed for an hour at 60 °C, cooled at room temperature, and neutralized with 1 N HCl. (3) Oxidative Stress Oxidative degradation was conducted by treating bo"
Paper-12,Paper-12,TEXT,base_hydrolysis,1 N NaOH,60 °C,,,,,"or an hour at 60 °C, cooled at room temperature, and neutralized with 1 N NaOH. (2) Alkaline degradation The mixture was hydrolyzed by adding 5 mL of 1 N NaOH, refluxed for an hour at 60 °C, cooled at room temperature, and neutralized with 1 N HCl. (3) Oxidative Stress Oxidative degradation was conducted by treating both drugs with 5 mL of 3% hydrogen peroxide and refluxing the solution at 60 °C f"
Paper-12,Paper-12,TEXT,oxidation,3% hydrogen peroxide,60 °C,60 min,,,,"ooled at room temperature, and neutralized with 1 N HCl. (3) Oxidative Stress Oxidative degradation was conducted by treating both drugs with 5 mL of 3% hydrogen peroxide and refluxing the solution at 60 °C for 60 min. (4) Thermal degradation The process was performed by subjecting both drugs to a hot air oven at 110 °C for 3 h. (5) Photodegradation The procedurse involved exposing both drug sampl"
Paper-12,Paper-12,TEXT,thermal,60 °C,60 °C,,,,,"ristics of the compounds. 2.9 Preparation of stock (1) Acid degradation The mixture was hydrolyzed by adding 5 mL of 1 N HCl, refluxed for an hour at 60 °C, cooled at room temperature, and neutralized with 1 N NaOH. (2) Alkaline degradation The mixture was hydrolyzed by adding 5 mL of 1 N NaOH, refluxed for an hour at 60 °C, cooled at room temperature, and neutralized with 1 N HCl. (3) Oxidative S"
Paper-12,Paper-12,TEXT,thermal,60 °C,60 °C,60 min,,,,"m temperature, and neutralized with 1 N NaOH. (2) Alkaline degradation The mixture was hydrolyzed by adding 5 mL of 1 N NaOH, refluxed for an hour at 60 °C, cooled at room temperature, and neutralized with 1 N HCl. (3) Oxidative Stress Oxidative degradation was conducted by treating both drugs with 5 mL of 3% hydrogen peroxide and refluxing the solution at 60 °C for 60 min. (4) Thermal degradation"
Paper-12,Paper-12,TEXT,thermal,60 °C,60 °C,60 min,,,, HCl. (3) Oxidative Stress Oxidative degradation was conducted by treating both drugs with 5 mL of 3% hydrogen peroxide and refluxing the solution at 60 °C for 60 min. (4) Thermal degradation The process was performed by subjecting both drugs to a hot air oven at 110 °C for 3 h. (5) Photodegradation The procedurse involved exposing both drug samples to UV light in a UV chamber for two days. 3 Resu
Paper-12,Paper-12,TEXT,thermal,110 °C,60 °C,60 min,,,,"oxide and refluxing the solution at 60 °C for 60 min. (4) Thermal degradation The process was performed by subjecting both drugs to a hot air oven at 110 °C for 3 h. (5) Photodegradation The procedurse involved exposing both drug samples to UV light in a UV chamber for two days. 3 Results Based on solubility and literature review, various solvent systems using acetonitrile, methanol, and water wer"
Paper-12,Paper-12,CAMELOT_TABLE,acid_hydrolysis,1 N HCl,110 °C,3 h,,,,"ir Center for validated according to ICH Q2 (R2) guidelines, and forced degradation studies were Advance Research, BMU, Vesu, conducted under acidic (1 N HCl), alkaline (1 N NaOH), oxidative (3% H₂O₂), thermal Bharthana, Surat 395007, Gujarat, (110 °C for 3 h), and photolytic (UV light exposure) conditions. India Results Efonidipine and Metoprolol eluted at 7.17 and 2.77 min, respectively, showing"
Paper-12,Paper-12,CAMELOT_TABLE,base_hydrolysis,1 N NaOH,110 °C,3 h,,,,"ted according to ICH Q2 (R2) guidelines, and forced degradation studies were Advance Research, BMU, Vesu, conducted under acidic (1 N HCl), alkaline (1 N NaOH), oxidative (3% H₂O₂), thermal Bharthana, Surat 395007, Gujarat, (110 °C for 3 h), and photolytic (UV light exposure) conditions. India Results Efonidipine and Metoprolol eluted at 7.17 and 2.77 min, respectively, showing good linearity for "
Paper-12,Paper-12,CAMELOT_TABLE,thermal,110 °C,110 °C,3 h,,,,"e Advance Research, BMU, Vesu, conducted under acidic (1 N HCl), alkaline (1 N NaOH), oxidative (3% H₂O₂), thermal Bharthana, Surat 395007, Gujarat, (110 °C for 3 h), and photolytic (UV light exposure) conditions. India Results Efonidipine and Metoprolol eluted at 7.17 and 2.77 min, respectively, showing good linearity for EFO (20–120 µg/mL, r² = 0.9981) and MET (12.5–75 µg/mL, r² = 0.9961), high "
Paper-12,Paper-12,CAMELOT_TABLE,thermal,110 °C,110 °C,3 h,,,,"² = 0.9981); MET: 12.5–75 µg/mL (r² = 0.9961) Degradation Oxidation, hydrolysis, photolysis, thermal Acidic, alkaline, oxidative, thermal Conditions (110 °C/3 h), photolytic (UV light) Results Good linearity (r² = 0.999), stability under High recovery (98–102%), stability stress not specified under thermal and photolytic condi- tions; degradation in acidic/alkaline Validation According to ICH guid"
Paper-13,Paper-13,TEXT,base_hydrolysis,1NNaOH,,,,,," USA), respectively. pH 9.0 and pH 2.0 peptide and polypeptide therapeutics, very few numerical ranges are stresssampleswerepreparedbypHadjustmentwith1NNaOHand1N 3"
Paper-13,Paper-13,TEXT,humidity,30%RH,,,30%RH,,,"twouldnotbe humidity atwhichthedrug substanceisequilibrated.For example,if countedintheMBRcalculationsince,asdescribedabove,resultsless equilibratedto30%RH,thewatercontentofthedrugsubstancecould than LOQ contribute a value of zero for that attribute into the MBR decreasebyseveralpercent(absolute)comparedtothelevelofwater calculation,causingthetotalsolventleveltobeunderrepresented. targetedatisolat"
Paper-13,Paper-13,TEXT,thermal,60°C,60°C,7 day,,,,"tionstudy,the UA E.M.Hetricketal. Journal of Pharmaceutical and Biomedical Analysis 252 (2025) 116501 0.055 0.050 0.045 0.040 0.035 0.030 0.025 0.020 60°C 7 day 0.015 60°C 3 day 0.010 60°C 1 day Ini�al 0.005 Blank 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00 52.00 Minutes Fig.1. OverlayofRP-HPLCchromatogramsofpeptidedrugproductsolutionstressedat60◦Cfor1,3,and"
Paper-13,Paper-13,TEXT,thermal,60°C,60°C,7 day,,,,"E.M.Hetricketal. Journal of Pharmaceutical and Biomedical Analysis 252 (2025) 116501 0.055 0.050 0.045 0.040 0.035 0.030 0.025 0.020 60°C 7 day 0.015 60°C 3 day 0.010 60°C 1 day Ini�al 0.005 Blank 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00 52.00 Minutes Fig.1. OverlayofRP-HPLCchromatogramsofpeptidedrugproductsolutionstressedat60◦Cfor1,3,and7days. Fig.2. Mas"
Paper-13,Paper-13,TEXT,thermal,60°C,60°C,7 day,,,,"Journal of Pharmaceutical and Biomedical Analysis 252 (2025) 116501 0.055 0.050 0.045 0.040 0.035 0.030 0.025 0.020 60°C 7 day 0.015 60°C 3 day 0.010 60°C 1 day Ini�al 0.005 Blank 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00 52.00 Minutes Fig.1. OverlayofRP-HPLCchromatogramsofpeptidedrugproductsolutionstressedat60◦Cfor1,3,and7days. Fig.2. Massbalanceresultsfo"
Paper-13,Paper-13,CAMELOT_TABLE,humidity,75 %RH,,,75 %RH,,,"ate was 0.4 mL/min and the column was maintained ◦ See note Thermal 60 C X ◦ at 40 C during analysis. With a 10-µL injection volume, ammonium was ◦ C/75 %RH X Thermal/Humidity 40 determined (% wt/wt) in the drug substance by comparison of the peak ◦ Note: The control sample stored at (cid:0) 20 C serves as the initial time point for the area in the sample to a calibration curve generated for ammon"
Paper-13,Paper-13,CAMELOT_TABLE,humidity,30 % RH,,,30 % RH,,,"y at which the drug substance is equilibrated. For example, if counted in the MBR calculation since, as described above, results less equilibrated to 30 % RH, the water content of the drug substance could than LOQ contribute a value of zero for that attribute into the MBR decrease by several percent (absolute) compared to the level of water calculation, causing the total solvent level to be underr"
Paper-2,Paper-2,TEXT,thermal,50°C,50°C,,,,,"tudies. For instance, high-performance were mentioned. Those conditions were effects liquid chromatography-ultraviolet (HPLC-UV) and of temperature (>50°C), humidity (≥75% relative HPLC-photodiode array detector (PDA) are two humidity), oxidation, photolysis, and diverse range of common equipment to study the stability indicating pH (solution/suspension).[9-11] method (SIM) development and validat"
Paper-2,Paper-2,TEXT,base_hydrolysis,0.1N sodium hydroxide,60°C,,,,,"ollows free radical the drug substances are treated with 0.1N hydrochloric mechanism, to produce a peroxide. Notably, it is acid or sulphuric acid or 0.1N sodium hydroxide at shown that light also catalyzes oxidation reactions. 50–60°C. The stability of molecule depends on the In non-oxidative process, several types of reactions strength of acid or alkali used in the study. The strength are observ"
Paper-2,Paper-2,TEXT,thermal,40°C,40°C,7 day,,,,"a common initiator for oxidation forced degradation study will be aborted or the respective drug sample studies. These studies should be conducted at 40°C for will be subjected to additional stress to analyze the 1–7 days. If more than 20% degradants are produced, nature of secondary degradants that are expected to then it should be considered as abnormal. produce during the study. If any case onl"
Paper-2,Paper-2,TEXT,thermal,80°C,80°C,,,,,"Origin of Degradation Products of degradation products. These studies should be Degradation is considered as one of the chief sources conducted at 40–80°C. The duration of thermal stress for impurities. Under different stress conditions, studies usually lasts for 1–2 months and are conducted namely humidity, heat, pH, isolation, storage, and at 70°C and at high humidity. The drug molecules transpo"
Paper-2,Paper-2,TEXT,thermal,70°C,70°C,,,,,"ties. Under different stress conditions, studies usually lasts for 1–2 months and are conducted namely humidity, heat, pH, isolation, storage, and at 70°C and at high humidity. The drug molecules transportation processes, drug molecules may which are solid in nature are subjected to both dry undergo degradation because of chemical instability. and wet heat conditions, while liquids are exposed to "
Paper-2,Paper-2,TEXT,thermal,60°C,60°C,,,,,"ism, to produce a peroxide. Notably, it is acid or sulphuric acid or 0.1N sodium hydroxide at shown that light also catalyzes oxidation reactions. 50–60°C. The stability of molecule depends on the In non-oxidative process, several types of reactions strength of acid or alkali used in the study. The strength are observed such as the homolytic breakage of C-X of acid or alkali should be maintained b"
Paper-2,Paper-2,TEXT,acid_hydrolysis,0.1M HCl,40°C,,,,,"on studies Type of degradation Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitr"
Paper-2,Paper-2,TEXT,base_hydrolysis,0.1M NaOH,40°C,,,,,"tion Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,"
Paper-2,Paper-2,TEXT,thermal,40°C,40°C,,,,," forced degradation studies Type of degradation Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Az"
Paper-2,Paper-2,TEXT,thermal,60°C,40°C,,,,,"d degradation studies Type of degradation Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisis"
Paper-2,Paper-2,TEXT,thermal,40°C,40°C,,,,,"s Type of degradation Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN"
Paper-2,Paper-2,TEXT,thermal,60°C,40°C,,,,," of degradation Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C"
Paper-2,Paper-2,TEXT,thermal,40°C,40°C,,,,,"imental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN con"
Paper-2,Paper-2,TEXT,thermal,60°C,40°C,,,,,"l conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 2"
Paper-2,Paper-2,TEXT,thermal,40°C,40°C,,,,,"ampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light "
Paper-2,Paper-2,TEXT,thermal,60°C,40°C,,,,,"g time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X IC"
Paper-2,Paper-2,TEXT,thermal,40°C,40°C,,,,,"API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5"
Paper-2,Paper-2,TEXT,thermal,60°C,40°C,,,,,"o acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light"
Paper-2,Paper-2,TEXT,thermal,40°C,40°C,,,,," 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Therm"
Paper-2,Paper-2,TEXT,thermal,60°C,40°C,,,,," 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis"
Paper-2,Paper-2,TEXT,thermal,25°C,40°C,5 H,,,,"0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 He"
Paper-2,Paper-2,TEXT,thermal,60°C,40°C,5 H,,,,"aOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat cha"
Paper-2,Paper-2,TEXT,thermal,25°C,40°C,5 H,,,,"l (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat ch"
Paper-2,Paper-2,TEXT,thermal,60°C,40°C,5 H,,,,"API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber "
Paper-2,Paper-2,TEXT,thermal,25°C,40°C,5 H,,,,"I) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3"
Paper-2,Paper-2,TEXT,thermal,60°C,60°C,5 H,,,,"C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Fig"
Paper-2,Paper-2,TEXT,thermal,25°C,40°C,5 H,,,,"8 40°C, 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Figure 1: Schematic represe"
Paper-2,Paper-2,TEXT,thermal,60°C,60°C,5 H,,,,", 60°C 1,3,5 Oxidation 3% HO 25°C, 60°C 1,3,5 2 2 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Figure 1: Schematic representatio"
Paper-2,Paper-2,TEXT,thermal,60°C,60°C,5 H,,,,"°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Figure 1: Schematic representation of degradation studies of drugs and drug products under different stress conditions Humidity interactions that occ"
Paper-2,Paper-2,TEXT,thermal,60°C,25°C,5 H,,,,"rol 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Figure 1: Schematic representation of degradation studies of drugs and drug products under different stress conditions Humidity interactions that occur between the excipient"
Paper-2,Paper-2,TEXT,thermal,75°C,5°C,5 H,,,,"5°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Figure 1: Schematic representation of degradation studies of drugs and drug products under different stress conditions Humidity interactions that occur between the excipients and"
Paper-2,Paper-2,TEXT,thermal,60°C,60°C,5 H,,,,"ight 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Figure 1: Schematic representation of degradation studies of drugs and drug products under different stress conditions Humidity interactions that occur between the excipients and the Humidity plays an impor"
Paper-2,Paper-2,TEXT,thermal,60°C,60°C,5 H,,,,"ght 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Figure 1: Schematic representation of degradation studies of drugs and drug products under different stress conditions Humidity interactions that occur between the excipients and the Humidity plays an important role in degradation"
Paper-2,Paper-2,TEXT,thermal,75°C,60°C,5 H,,,," X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Figure 1: Schematic representation of degradation studies of drugs and drug products under different stress conditions Humidity interactions that occur between the excipients and the Humidity plays an important role in degradation drug"
Paper-2,Paper-2,TEXT,thermal,40°C,40°C,,,,,"ffers can be used for FOR FORCED DECOMPOSITION good baseline separation and peak symmetry. At STUDIES times, the column temperature is adjusted to 30–40°C to get good reproducibility of the results. Degradant During forced decomposition and stability studies, peaks are pushed in the chromatogram to get good active pharmaceutical ingredient is subjected to various resolution. Sometimes degradants p"
Paper-2,Paper-2,TEXT,thermal,80°C,80°C,,,,,"wo as follows: degradants produced which were characterized as 1. Aceclofenac: Aceclofenac is stable at dry heat or 2-epi and ∆2,3 isomers.[32] below 80°C and in the absence of light.[18] 16. Lansoprazole: In acid hydrolytic conditions, 2. Diacerein: Diacerein was unstable at alkaline one degradation product was produced and was hydrolysis, photolytic, and thermal conditions. It identified as 1-me"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,50°C,50°C,,,,,"tudies. For instance, high-performance were mentioned. Those conditions were effects liquid chromatography-ultraviolet (HPLC-UV) and of temperature (>50°C), humidity (≥75% relative HPLC-photodiode array detector (PDA) are two humidity), oxidation, photolysis, and diverse range of common equipment to study the stability indicating pH (solution/suspension).[9-11] method (SIM) development and validat"
Paper-2,Paper-2,CAMELOT_TABLE,base_hydrolysis,0.1N sodium hydroxide,60°C,,,,,"ollows free radical the drug substances are treated with 0.1N hydrochloric mechanism, to produce a peroxide. Notably, it is acid or sulphuric acid or 0.1N sodium hydroxide at shown that light also catalyzes oxidation reactions. 50–60°C. The stability of molecule depends on the In non-oxidative process, several types of reactions strength of acid or alkali used in the study. The strength are observ"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,40°C,40°C,7 day,,,,"a common initiator for oxidation forced degradation study will be aborted or the respective drug sample studies. These studies should be conducted at 40°C for will be subjected to additional stress to analyze the 1–7 days. If more than 20% degradants are produced, nature of secondary degradants that are expected to then it should be considered as abnormal. produce during the study. If any case onl"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,80°C,80°C,,,,,"nds to increase which in turn leads to the production Origin of Degradation Products of degradation products. These studies should be conducted at 40–80°C. The duration of thermal stress Degradation is considered as one of the chief sources studies usually lasts for 1–2 months and are conducted for impurities. Under different stress conditions, at 70°C and at high humidity. The drug molecules name"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,70°C,70°C,,,,,"s considered as one of the chief sources studies usually lasts for 1–2 months and are conducted for impurities. Under different stress conditions, at 70°C and at high humidity. The drug molecules namely humidity, heat, pH, isolation, storage, and which are solid in nature are subjected to both dry transportation processes, drug molecules may and wet heat conditions, while liquids are exposed to un"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,60°C,,,,,"ism, to produce a peroxide. Notably, it is acid or sulphuric acid or 0.1N sodium hydroxide at shown that light also catalyzes oxidation reactions. 50–60°C. The stability of molecule depends on the In non-oxidative process, several types of reactions strength of acid or alkali used in the study. The strength are observed such as the homolytic breakage of C-X of acid or alkali should be maintained b"
Paper-2,Paper-2,CAMELOT_TABLE,acid_hydrolysis,0.1M HCl,40°C,,,,,"on studies Type of degradation Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitril"
Paper-2,Paper-2,CAMELOT_TABLE,base_hydrolysis,0.1M NaOH,40°C,,,,,"tion Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 "
Paper-2,Paper-2,CAMELOT_TABLE,oxidation,3% H2O2,40°C,,,,,"1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,40°C,40°C,,,,," forced degradation studies Type of degradation Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azob"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,40°C,,,,,"d degradation studies Type of degradation Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisob"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,40°C,40°C,,,,,"s Type of degradation Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) "
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,40°C,,,,," of degradation Experimental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, "
Paper-2,Paper-2,CAMELOT_TABLE,thermal,40°C,40°C,,,,,"imental conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN contr"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,40°C,,,,,"l conditions Storage conditions Sampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,40°C,40°C,,,,,"ampling time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 "
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,40°C,,,,,"g time (days) Hydrolysis Control API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH "
Paper-2,Paper-2,CAMELOT_TABLE,thermal,40°C,40°C,,,,,"API (no acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 L"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,40°C,,,,,"o acid/base) 40°C, 60°C 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,40°C,40°C,,,,," 1,3,5 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermol"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,40°C,,,,," 0.1M HCl 40°C, 60°C 1,3,5 0.1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis H"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,25°C,40°C,5 H,,,,"1M NaOH 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat c"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,40°C,5 H,,,,"H 40°C, 60°C 1,3,5 Acid control (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,25°C,40°C,5 H,,,,"rol (no API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat ch"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,40°C,5 H,,,,"o API) 40°C, 60°C 1,3,5 Base control (no API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber "
Paper-2,Paper-2,CAMELOT_TABLE,thermal,25°C,40°C,5 H,,,,"API) 40°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,0°C,5 H,,,,"0°C, 60°C 1,3,5 pH: 2,4,6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,25°C,40°C,5 H,,,,"6,8 40°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,60°C,5 H,,,,"°C, 60°C 1,3,5 Oxidation 3% H2O2 25°C, 60°C 1,3,5 Peroxide control 25°C, 60°C 1,3,5 Azobisisobutyronitrile (ABIN) 25°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,60°C,5 H,,,,"°C, 60°C 1,3,5 ABIN control 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,25°C,5 H,,,,"rol 25°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,75°C,5°C,5 H,,,,"5°C, 60°C 1,3,5 Photolysis Light 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,60°C,5 H,,,,"ight 1 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,60°C,60°C,5 H,,,,"ght 3 X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5"
Paper-2,Paper-2,CAMELOT_TABLE,thermal,75°C,60°C,5 H,,,," X ICH NA 1,3,5 Light 3 X ICH NA 1,3,5 Thermolysis Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5 Heat chamber 60°C 1,3,5 Heat chamber 60°C/75°C% RH 1,3,5"
Paper-3,Paper-3,TEXT,humidity,75% relative humidity,,,75% relative humidity,,,"ect the results of temperature (above that for accelerated testing, i.e., >50 C), The developed and validated analytical method permits the humidity (75% relative humidity), oxidation and photolysis. analysis of each degradation products. Unfortunately, there Wide pH range should be considered in the testing of solution or is less guidance available to establish true selective forced suspension. U"
Paper-3,Paper-3,TEXT,acid_hydrolysis,0.1M HCl,,5 H,,,," Degradation Studies. Degradation Type Experimental Conditions Storage Conditions Sampling Time (days) Control API (no acid or base) 1,3,5 40˚C, 60˚C 0.1M HCl 1,3,5 40˚C, 60˚C 0.1 M NaOH 1,3,5 Hydrolysis 40˚C, 60˚C Acid control (no API) 1,3,5 40˚C, 60˚C Base control (no API) 1,3,5 40˚C, 60˚C pH: 2,4,6,8 1,3,5 3% H2O2 25˚C, 60˚C 1,3,5 25˚C, 60˚C 1,3,5 Peroxide control Oxidation 25˚C, 60˚C 1,3,5 Azo"
Paper-3,Paper-3,TEXT,base_hydrolysis,0.1 M NaOH,,5 H,,,,"adation Type Experimental Conditions Storage Conditions Sampling Time (days) Control API (no acid or base) 1,3,5 40˚C, 60˚C 0.1M HCl 1,3,5 40˚C, 60˚C 0.1 M NaOH 1,3,5 Hydrolysis 40˚C, 60˚C Acid control (no API) 1,3,5 40˚C, 60˚C Base control (no API) 1,3,5 40˚C, 60˚C pH: 2,4,6,8 1,3,5 3% H2O2 25˚C, 60˚C 1,3,5 25˚C, 60˚C 1,3,5 Peroxide control Oxidation 25˚C, 60˚C 1,3,5 Azobisisobutyronitrile (AIBN)"
Paper-3,Paper-3,TEXT,oxidation,3% H2O2,,5 H,,,,"3,5 40˚C, 60˚C 0.1 M NaOH 1,3,5 Hydrolysis 40˚C, 60˚C Acid control (no API) 1,3,5 40˚C, 60˚C Base control (no API) 1,3,5 40˚C, 60˚C pH: 2,4,6,8 1,3,5 3% H2O2 25˚C, 60˚C 1,3,5 25˚C, 60˚C 1,3,5 Peroxide control Oxidation 25˚C, 60˚C 1,3,5 Azobisisobutyronitrile (AIBN) 25˚C, 60˚C 1,3,5 AIBN control 25˚C, 60˚C 1,3,5 Light 1 × ICH NA 1,3,5 Photolytic Light 3 × ICH NA 1,3,5 Light 3 × ICH NA 1,3,5 Heat ch"
Paper-3,Paper-3,TEXT,humidity,75% RH,,5 H,75% RH,,,"N control 25˚C, 60˚C 1,3,5 Light 1 × ICH NA 1,3,5 Photolytic Light 3 × ICH NA 1,3,5 Light 3 × ICH NA 1,3,5 Heat chamber 60˚C 1,3,5 Heat chamber 60˚C /75% RH 1,3,5 Thermal Heat chamber 60˚C 1,3,5 Heat chamber 60˚C /75% RH 1,3,5 Figure 1: Forced Degradation Submitted Data. Citation: Iram F, Iram H, Iqbal A, Husain A (2016) Forced Degradation Studies. J Anal Pharm Res 3(6): 00073. DOI: 10.15406/japlr"
Paper-3,Paper-3,TEXT,humidity,75% RH,,5 H,75% RH,,,"ht 3 × ICH NA 1,3,5 Light 3 × ICH NA 1,3,5 Heat chamber 60˚C 1,3,5 Heat chamber 60˚C /75% RH 1,3,5 Thermal Heat chamber 60˚C 1,3,5 Heat chamber 60˚C /75% RH 1,3,5 Figure 1: Forced Degradation Submitted Data. Citation: Iram F, Iram H, Iqbal A, Husain A (2016) Forced Degradation Studies. J Anal Pharm Res 3(6): 00073. DOI: 10.15406/japlr.2016.03.00073"
Paper-3,Paper-3,PDFPLUMBER_TABLE,acid_hydrolysis,0.1M HCl,,,,,,"orced Degra Degradation Type dation Studies. Experimental Conditions Storage Conditions Sampling Time (days) Hydrolysis Control API (no acid or base) 0.1M HCl 0.1 M NaOH Acid control (no API) Base control (no API) 40˚C, 60˚C 40˚C, 60˚C 40˚C, 60˚C 40˚C, 60˚C 1,3,5 1,3,5 1,3,5 1,3,5 1,3,5 Oxidation pH: 2,4,6,8 3% H2O2 Peroxide control Azobisisobutyronitrile (AIBN) 40˚C, 60˚C 25˚C, 60˚C 25˚C, 60˚C 25"
Paper-3,Paper-3,PDFPLUMBER_TABLE,base_hydrolysis,0.1 M NaOH,,,,,,"ra Degradation Type dation Studies. Experimental Conditions Storage Conditions Sampling Time (days) Hydrolysis Control API (no acid or base) 0.1M HCl 0.1 M NaOH Acid control (no API) Base control (no API) 40˚C, 60˚C 40˚C, 60˚C 40˚C, 60˚C 40˚C, 60˚C 1,3,5 1,3,5 1,3,5 1,3,5 1,3,5 Oxidation pH: 2,4,6,8 3% H2O2 Peroxide control Azobisisobutyronitrile (AIBN) 40˚C, 60˚C 25˚C, 60˚C 25˚C, 60˚C 25˚C, 60˚C "
Paper-3,Paper-3,PDFPLUMBER_TABLE,oxidation,3% H2O2,,,,,,".1 M NaOH Acid control (no API) Base control (no API) 40˚C, 60˚C 40˚C, 60˚C 40˚C, 60˚C 40˚C, 60˚C 1,3,5 1,3,5 1,3,5 1,3,5 1,3,5 Oxidation pH: 2,4,6,8 3% H2O2 Peroxide control Azobisisobutyronitrile (AIBN) 40˚C, 60˚C 25˚C, 60˚C 25˚C, 60˚C 25˚C, 60˚C 1,3,5 1,3,5 1,3,5 1,3,5 AIBN control Light 1 × ICH 25˚C, 60˚C 25˚C, 60˚C NA 1,3,5 1,3,5 1,3,5 Photolytic Thermal Light 3 × ICH Light 3 × ICH Heat chamb"
Paper-3,Paper-3,PDFPLUMBER_TABLE,humidity,75% RH,,,75% RH,,,"ICH 25˚C, 60˚C 25˚C, 60˚C NA 1,3,5 1,3,5 1,3,5 Photolytic Thermal Light 3 × ICH Light 3 × ICH Heat chamber Heat chamber Heat chamber NA NA 60˚C 60˚C /75% RH 60˚C 1,3,5 1,3,5 1,3,5 1,3,5 1,3,5"
Paper-3,Paper-3,CAMELOT_TABLE,humidity,75% relative humidity,,,75% relative humidity,,,"ect the results of temperature (above that for accelerated testing, i.e., >50 C), The developed and validated analytical method permits the humidity (75% relative humidity), oxidation and photolysis. analysis of each degradation products. Unfortunately, there Wide pH range should be considered in the testing of solution or is less guidance available to establish true selective forced suspension. U"
Paper-3,Paper-3,CAMELOT_TABLE,acid_hydrolysis,0.1M HCl,,5 H,,,," Degradation Studies. Degradation Type Experimental Conditions Storage Conditions Sampling Time (days) Control API (no acid or base) 1,3,5 40˚C, 60˚C 0.1M HCl 1,3,5 40˚C, 60˚C 0.1 M NaOH 1,3,5 Hydrolysis 40˚C, 60˚C Acid control (no API) 1,3,5 40˚C, 60˚C Base control (no API) 1,3,5 40˚C, 60˚C pH: 2,4,6,8 1,3,5 25˚C, 60˚C 1,3,5 3% H2O2 25˚C, 60˚C 1,3,5 Peroxide control Oxidation 25˚C, 60˚C 1,3,5 Azo"
Paper-3,Paper-3,CAMELOT_TABLE,base_hydrolysis,0.1 M NaOH,,5 H,,,,"adation Type Experimental Conditions Storage Conditions Sampling Time (days) Control API (no acid or base) 1,3,5 40˚C, 60˚C 0.1M HCl 1,3,5 40˚C, 60˚C 0.1 M NaOH 1,3,5 Hydrolysis 40˚C, 60˚C Acid control (no API) 1,3,5 40˚C, 60˚C Base control (no API) 1,3,5 40˚C, 60˚C pH: 2,4,6,8 1,3,5 25˚C, 60˚C 1,3,5 3% H2O2 25˚C, 60˚C 1,3,5 Peroxide control Oxidation 25˚C, 60˚C 1,3,5 Azobisisobutyronitrile (AIBN)"
Paper-3,Paper-3,CAMELOT_TABLE,oxidation,3% H2O2,,5 H,,,,"1 M NaOH 1,3,5 Hydrolysis 40˚C, 60˚C Acid control (no API) 1,3,5 40˚C, 60˚C Base control (no API) 1,3,5 40˚C, 60˚C pH: 2,4,6,8 1,3,5 25˚C, 60˚C 1,3,5 3% H2O2 25˚C, 60˚C 1,3,5 Peroxide control Oxidation 25˚C, 60˚C 1,3,5 Azobisisobutyronitrile (AIBN) 25˚C, 60˚C 1,3,5 AIBN control 25˚C, 60˚C 1,3,5 Light 1 × ICH NA 1,3,5 Photolytic Light 3 × ICH NA 1,3,5 Light 3 × ICH NA 1,3,5 Heat chamber 60˚C 1,3,5 "
Paper-3,Paper-3,CAMELOT_TABLE,humidity,75% RH,,5 H,75% RH,,,"N control 25˚C, 60˚C 1,3,5 Light 1 × ICH NA 1,3,5 Photolytic Light 3 × ICH NA 1,3,5 Light 3 × ICH NA 1,3,5 Heat chamber 60˚C 1,3,5 Heat chamber 60˚C /75% RH 1,3,5 Thermal Heat chamber 60˚C 1,3,5 Heat chamber 60˚C /75% RH 1,3,5"
Paper-3,Paper-3,CAMELOT_TABLE,humidity,75% RH,,5 H,75% RH,,,"ht 3 × ICH NA 1,3,5 Light 3 × ICH NA 1,3,5 Heat chamber 60˚C 1,3,5 Heat chamber 60˚C /75% RH 1,3,5 Thermal Heat chamber 60˚C 1,3,5 Heat chamber 60˚C /75% RH 1,3,5"
Paper-4,Paper-4,TEXT,acid_hydrolysis,1 M HCl,,7 day,,,,"ontrol and routine analysis of pharmaceutical products. Acid hydrolysis Flibanserin had been approved as the first drug by United In brief, 200 µL of 1 M HCl solution was added into State Food and Drug Administration (USFDA) for the 50 µL of 1 mg/mL flibanserin solution and the acid treatment of female sexual interest/arousal disorder of hydrolysis was performed for 7 days at room temperature any "
Paper-4,Paper-4,TEXT,base_hydrolysis,1 M NaOH,,7 day,,,,"n A 2A could regulate the dopamine and norepinephrine. It Base hydrolysis stimulates the postsynaptic 5-HT receptors, causing the In brief, 200 µL of 1 M NaOH solution was added into 1A downstream release of dopamine and norepinephrine. It 50 µL of 1 mg/mL flibanserin solution and the base was reported that flibanserin was able to cause a gradual hydrolysis was performed for 7 days at room tempera"
Paper-4,Paper-4,TEXT,thermal,70°C,70°C,7 day,,,, interest/arousal disorder of hydrolysis was performed for 7 days at room temperature any severity.9 It is able to exert its actions by acting as and 70°C. The reaction mixtures were topped up with an agonist at postsynaptic receptor and antagonist at diluents until 5 mL before subjected to HPLC analysis. 5-hydroxytryptamine 2 (5-HT ) receptor. Flibanserin A 2A could regulate the dopamine and nore
Paper-4,Paper-4,TEXT,thermal,70°C,70°C,7 day,,,,"nserin was able to cause a gradual hydrolysis was performed for 7 days at room temperature reduction in the level of serotonin,10 and inhibit the and 70°C. The reaction mixtures were topped up with postsynaptic 5-HT receptors in the prefrontal cortex, diluents until 5 mL before the HPLC analysis. 2A which could result in the reduction of serotonin.11 Flibanserin had also been used as the treatment"
Paper-4,Paper-4,TEXT,thermal,50°C,50°C,5 day,,,,"ss, 1 mg/mL flibanserin solution. The reaction mixtures limit of detection (LOD) and limit of quantification were then placed at room temperature and 50°C for (LOQ). 5 days. The reaction mixtures were topped up with Linearity diluents until 5 mL before the HPLC analysis. Linearity was well-established by plotting peak Transition metal oxidation area against the corresponding concentrations of In b"
Paper-4,Paper-4,TEXT,thermal,70°C,70°C,7 day,,,," µL of 1 mg/mL flibanserin solution. The reaction regression equation and correlation coefficient. Seven mixtures were placed at room temperature and 70°C concentrations and triplicates for each concentration for 7 days. The reaction mixtures were topped up with were evaluated. diluents until 5 mL before the HPLC analysis. Accuracy, precision and repeatability Instrumentation Accuracy of the metho"
Paper-4,Paper-4,TEXT,thermal,25°C,25°C,,,,,"aphic separation was performed on Luna C- (4.6 mm x 250 mm, 5 µm, Phenomenex, California, The precision of the method was determined from 18 USA) and 25°C was maintained in the column. The flibanserin standards of the highest, middle and lowest gradient elution of two pumps were set up with concentrations in the established linearity range. Three acetonitrile and ammonium acetate buffer separately"
Paper-4,Paper-4,TEXT,thermal,25°C,25°C,,,,," establish the intra-day and inter-day bulk drug under acidic, alkaline and oxidative conditions precision. The working standards used ranged from at 25°C. Drugs could be degraded at slower rate at 5 - 20 µg/mL and %RSD was calculated. The %RSD ambient temperature. Therefore, higher temperature was values for intra-day and inter-day precision values were used to accelerate the degradation of drugs"
Paper-4,Paper-4,TEXT,thermal,50°C,50°C,24 h,,,,"eir stability under certain stress conditions. Accelerated (Table 2), while inter-day ranged 0.92-1.61% (Table 3). degradation at higher temperature (50°C and 70°C) was Low %RSD in accuracy and precision studies indicated performed when no significant degradation was noticed that the method had promising accuracy, precision, at 25°C after 24 hr. reproducibility and repeatability. From our study, f"
Paper-4,Paper-4,TEXT,thermal,70°C,50°C,24 h,,,,"lity under certain stress conditions. Accelerated (Table 2), while inter-day ranged 0.92-1.61% (Table 3). degradation at higher temperature (50°C and 70°C) was Low %RSD in accuracy and precision studies indicated performed when no significant degradation was noticed that the method had promising accuracy, precision, at 25°C after 24 hr. reproducibility and repeatability. From our study, flibanseri"
Paper-4,Paper-4,TEXT,thermal,25°C,25°C,24 h,,,," accuracy and precision studies indicated performed when no significant degradation was noticed that the method had promising accuracy, precision, at 25°C after 24 hr. reproducibility and repeatability. From our study, flibanserin remained stable under acidic, alkaline, radical and transition metal oxidations Robustness at 25°C. Exception was significant degradation was Robustness of an analytical"
Paper-4,Paper-4,TEXT,thermal,25°C,25°C,,,,,"cibility and repeatability. From our study, flibanserin remained stable under acidic, alkaline, radical and transition metal oxidations Robustness at 25°C. Exception was significant degradation was Robustness of an analytical procedure measures the observed in H O oxidation. Reduction of flibanserin 2 2 estimation of capacity to remain unaffected by minor, concentration over time was noticed and o"
Paper-4,Paper-4,TEXT,thermal,25°C,25°C,2 H,,,,. Table 5: Proposed models of flibanserin degradation kinetics under HO and radical oxidation. 2 2 Reaction order Linear equation r2 HO oxidation (at 25°C) 2 2 Zero-order y = -0.7665x + 0.9721 9.2409 First-order y = -0.1254x + 0.9963 2.2515 Second-order y = 0.022x + 0.0982 0.9870 AIBN oxidation (at 50°C) Zero-order y = - 1.6677x + 0.9807 8.7776 First-order y = - 0.3214x + 0.9993 2.2363 Second-orde
Paper-4,Paper-4,TEXT,thermal,50°C,25°C,,,,,25°C) 2 2 Zero-order y = -0.7665x + 0.9721 9.2409 First-order y = -0.1254x + 0.9963 2.2515 Second-order y = 0.022x + 0.0982 0.9870 AIBN oxidation (at 50°C) Zero-order y = - 1.6677x + 0.9807 8.7776 First-order y = - 0.3214x + 0.9993 2.2363 Second-order y = 0.0698x + 0.0854 0.9734 FeCl oxidation (at 75°C) 3 Zero-order y = -0.8203x + 0.9468 9.8364 First-order y = 0.0236x + 0.0829 0.7860 Figure 1: Chr
Paper-4,Paper-4,TEXT,thermal,75°C,50°C,0 h,,,," 50°C) Zero-order y = - 1.6677x + 0.9807 8.7776 First-order y = - 0.3214x + 0.9993 2.2363 Second-order y = 0.0698x + 0.0854 0.9734 FeCl oxidation (at 75°C) 3 Zero-order y = -0.8203x + 0.9468 9.8364 First-order y = 0.0236x + 0.0829 0.7860 Figure 1: Chromatogram of H 2 O 2 degraded samples at (a) Second-order y = -0.1336x + 0.8732 0 hr, (b) 0.5 hr, (c) 1 hr, (d) 2 hr, (e) 4 hr, and (f) 8 hr. (Unk 1 "
Paper-4,Paper-4,PDFPLUMBER_TABLE,thermal,25°C,25°C,2 H,,,,Table 5: Proposed models of flibanserin degradation kinetics under HO and radical oxidation. 2 2 Reaction order Linear equation r2 HO oxidation (at 25°C) 2 2 Zero-order y = -0.7665x + 9.2409 0.9721 First-order y = -0.1254x + 2.2515 0.9963 Second-order y = 0.022x + 0.0982 0.9870 AIBN oxidation (at 50°C) Zero-order y = - 1.6677x + 8.7776 0.9807 First-order y = - 0.3214x + 2.2363 0.9993 Second-orde
Paper-4,Paper-4,PDFPLUMBER_TABLE,thermal,50°C,25°C,,,,,25°C) 2 2 Zero-order y = -0.7665x + 9.2409 0.9721 First-order y = -0.1254x + 2.2515 0.9963 Second-order y = 0.022x + 0.0982 0.9870 AIBN oxidation (at 50°C) Zero-order y = - 1.6677x + 8.7776 0.9807 First-order y = - 0.3214x + 2.2363 0.9993 Second-order y = 0.0698x + 0.0854 0.9734 FeCl oxidation (at 75°C) 3 Zero-order y = -0.8203x + 9.8364 0.9468 First-order y = 0.0236x + 0.0829 0.7860 Second-order 
Paper-4,Paper-4,PDFPLUMBER_TABLE,thermal,75°C,50°C,,,,, 50°C) Zero-order y = - 1.6677x + 8.7776 0.9807 First-order y = - 0.3214x + 2.2363 0.9993 Second-order y = 0.0698x + 0.0854 0.9734 FeCl oxidation (at 75°C) 3 Zero-order y = -0.8203x + 9.8364 0.9468 First-order y = 0.0236x + 0.0829 0.7860 Second-order y = -0.1336x + 2.3446 0.8732
Paper-4,Paper-4,TEXT,thermal,100°C,100°C,21 h,,,,"ffects.22,23 Ahmed et al.21 had also reported that flibanserin was Degradation kinetics aimed to predict the intrinsic degraded by 30% H O heating at 100°C, and yielded two stability of flibanserin in order to anticipate problems 2 2 N-oxide products. The amide bond in benzimidazole that may arise. Our degradation kinetics showed that the ring of flibanserin was hydrolysed and the cleavage had mod"
Paper-4,Paper-4,TEXT,thermal,70°C,70°C,,,,,"performed in acidic, alkaline, radical initiator and transition metal oxidations. Flibanserin remained stable under acidic and basic conditions up to 70°C. Significant degradation was noticed in oxidation by AIBN radical initiator and FeCl at higher temperatures. 3 Six degradation impurities were spotted in both treatments (Figure 4 and Figure 5). Degradation kinetics showed that the model that be"
Paper-4,Paper-4,TEXT,thermal,50°C,50°C,0 day,,,,"romatogram of AIBN degraded samples with thermal treatment at (a) 0 day, (b) 1 day, (c) 3 days, (d) 5 days, t = 7.8 hr, t = 3.8 hr, and t = 2 days at 50°C. 90 95 1/2 and (e) 7 days. (Unk 1 represents Unknown 1; Unk 2 represents The degradation kinetics of FeCl was best fitted to the Unknown 2; Unk 3 represents Unknown 3; Unk 4 represents 3 zero-order kinetic, as the R2 value (R2 = 0.9468) for this"
Paper-4,Paper-4,TEXT,thermal,70°C,70°C,27.9 h,,,,"). The shelf life and half- life determined under the transition metal oxidation condition were t = 27.9 hr, t = 14.0 hr, and t = 6 days 90 95 1/2 at 70°C. The physicochemical properties of pharmaceutical excipients could result in formulation instability that could potentially disrupt the quality and efficacy. Interaction between drug substances and excipients and their incompatibilities could be"
Paper-4,Paper-4,TEXT,thermal,50°C,50°C,,,,,"ch H O at room temperature conditions, and FeCl and 2 2 3 could be considered to include in the pharmaceutical AIBN at accelerated stress conditions (50°C and above). formulations is ethylenediaminetetraacetic acid (EDTA) Oxidation of flibanserin under H O had yielded two 2 2 which could bind to the peroxides present in the impurities with m/z 407.17. It was deduced that the formulation. Besides, "
Paper-4,Paper-4,CAMELOT_TABLE,acid_hydrolysis,1 M HCl,,7 day,,,,"ontrol and routine analysis of pharmaceutical products. Acid hydrolysis Flibanserin had been approved as the first drug by United In brief, 200 µL of 1 M HCl solution was added into State Food and Drug Administration (USFDA) for the 50 µL of 1 mg/mL flibanserin solution and the acid treatment of female sexual interest/arousal disorder of hydrolysis was performed for 7 days at room temperature any "
Paper-4,Paper-4,CAMELOT_TABLE,base_hydrolysis,1 M NaOH,,7 day,,,,"erin Base hydrolysis could regulate the dopamine and norepinephrine. It stimulates the postsynaptic 5-HT1A receptors, causing the In brief, 200 µL of 1 M NaOH solution was added into downstream release of dopamine and norepinephrine. It 50 µL of 1 mg/mL flibanserin solution and the base was reported that flibanserin was able to cause a gradual hydrolysis was performed for 7 days at room temperatur"
Paper-4,Paper-4,CAMELOT_TABLE,oxidation,3% H2O2,,11 H,,,,"ction of serotonin.11 H2O2 oxidation Flibanserin had also been used as the treatment of mental disorders such as Schizophrenia, depression, 200 µL of 3% H2O2 solution was added into 50 µL of anxiety as well as Parkinson’s disease.12 1 mg/mL flibanserin solution. The reaction mixtures were placed at room temperature up to 8 hr. Samples The objectives of this study were to optimize the stability wer"
Paper-4,Paper-4,CAMELOT_TABLE,thermal,70°C,70°C,7 day,,,, interest/arousal disorder of hydrolysis was performed for 7 days at room temperature any severity.9 It is able to exert its actions by acting as and 70°C. The reaction mixtures were topped up with an agonist at postsynaptic receptor and antagonist at diluents until 5 mL before subjected to HPLC analysis. 5-hydroxytryptamine 2A(5-HT2A) receptor. Flibanserin Base hydrolysis could regulate the dopam
Paper-4,Paper-4,CAMELOT_TABLE,thermal,70°C,70°C,7 day,,,,"nserin was able to cause a gradual hydrolysis was performed for 7 days at room temperature reduction in the level of serotonin,10 and inhibit the and 70°C. The reaction mixtures were topped up with postsynaptic 5-HT2A receptors in the prefrontal cortex, diluents until 5 mL before the HPLC analysis. which could result in the reduction of serotonin.11 H2O2 oxidation Flibanserin had also been used as"
Paper-4,Paper-4,CAMELOT_TABLE,thermal,50°C,50°C,5 day,,,,it of detection (LOD) and limit of quantification 1 mg/mL flibanserin solution. The reaction mixtures (LOQ). were then placed at room temperature and 50°C for 5 days. The reaction mixtures were topped up with Linearity diluents until 5 mL before the HPLC analysis. Linearity was well-established by plotting peak Transition metal oxidation area against the corresponding concentrations of flibanserin
Paper-4,Paper-4,CAMELOT_TABLE,thermal,70°C,70°C,7 day,,,,"0 µL of 1 mg/mL flibanserin solution. The reaction concentrations and triplicates for each concentration mixtures were placed at room temperature and 70°C were evaluated. for 7 days. The reaction mixtures were topped up with diluents until 5 mL before the HPLC analysis. Accuracy, precision and repeatability Instrumentation Accuracy of the method evaluate the closeness of RP-HPLC condition agreemen"
Paper-4,Paper-4,CAMELOT_TABLE,thermal,25°C,25°C,,,,," the method was determined from C-18 (4.6 mm x 250 mm, 5 µm, Phenomenex, California, flibanserin standards of the highest, middle and lowest USA) and 25°C was maintained in the column. The concentrations in the established linearity range. Three gradient elution of two pumps were set up with flibanserin concentrations (5, 10 and 20 µg/mL), acetonitrile and ammonium acetate buffer separately determ"
Paper-4,Paper-4,CAMELOT_TABLE,thermal,25°C,25°C,,,,," establish the intra-day and inter-day bulk drug under acidic, alkaline and oxidative conditions precision. The working standards used ranged from at 25°C. Drugs could be degraded at slower rate at 5 - 20 µg/mL and %RSD was calculated. The %RSD ambient temperature. Therefore, higher temperature was values for intra-day and inter-day precision values were used to accelerate the degradation of drugs"
Paper-4,Paper-4,CAMELOT_TABLE,thermal,50°C,50°C,24 h,,,,"eir stability under certain stress conditions. Accelerated (Table 2), while inter-day ranged 0.92-1.61% (Table 3). degradation at higher temperature (50°C and 70°C) was Low %RSD in accuracy and precision studies indicated performed when no significant degradation was noticed at 25°C after 24 hr. that the method had promising accuracy, precision, reproducibility and repeatability. From our study, f"
Paper-4,Paper-4,CAMELOT_TABLE,thermal,70°C,50°C,24 h,,,,"lity under certain stress conditions. Accelerated (Table 2), while inter-day ranged 0.92-1.61% (Table 3). degradation at higher temperature (50°C and 70°C) was Low %RSD in accuracy and precision studies indicated performed when no significant degradation was noticed at 25°C after 24 hr. that the method had promising accuracy, precision, reproducibility and repeatability. From our study, flibanseri"
Paper-4,Paper-4,CAMELOT_TABLE,thermal,25°C,50°C,24 h,,,," higher temperature (50°C and 70°C) was Low %RSD in accuracy and precision studies indicated performed when no significant degradation was noticed at 25°C after 24 hr. that the method had promising accuracy, precision, reproducibility and repeatability. From our study, flibanserin remained stable under acidic, alkaline, radical and transition metal oxidations Robustness at 25°C. Exception was sign"
Paper-4,Paper-4,CAMELOT_TABLE,thermal,25°C,25°C,,,,,"cibility and repeatability. From our study, flibanserin remained stable under acidic, alkaline, radical and transition metal oxidations Robustness at 25°C. Exception was significant degradation was Robustness of an analytical procedure measures the observed in H2O2 oxidation. Reduction of flibanserin estimation of capacity to remain unaffected by minor, concentration over time was noticed and one "
Paper-5,Paper-5,TEXT,acid_hydrolysis,1N HCl,,30 min,,,,"bout 48mg of From the test stock solution, 1 ml was taken in a Favipiravir API into a 100ml volumetric flask.Add 10 ml volumetric flask, adds 1 ml of 1N HCl, and about 80ml of diluent and sonicate to dissolve. heated at 600C for 30 min on a water bath. The Dilute to volume with the diluent and mix. flask was removed from the water bath and Transfer 5ml of above solution into a 50ml allowed to cool"
Paper-5,Paper-5,TEXT,acid_hydrolysis,1N HCl,,,,,, bath and volumetric flask dilute with diluent and mix. Filter allowed to cool at room temperature. Add 1 ml of the solution through a 0.45 µ filter. 1N HCl to neutralize the solution and diluted to volume with diluents and mix 10 ml solution were injected into the system and the chromatograms were recorded to assess the stability of sample [10]. 5.4.3 Peroxide (oxidation) degradation studies (3%v
Paper-5,Paper-5,TEXT,base_hydrolysis,1N NaOH,,,,,,"h and Transfer 5ml of above solution into a 50ml allowed to cool at room temperature. Add 1 ml of volumetric flask,dilute to volume with diluent, and 1N NaOH to neutralize the solution and diluted to mix. volume with diluents and mix 10 ml solution were injected into the system and the chromatograms 5.2 Preparation of Sample Solution for were recorded to assess the stability of the Assay sample [1"
Paper-5,Paper-5,TEXT,base_hydrolysis,1 N NaOH,,15 min,,,," into a 200ml From the test stock solution, 1 ml was taken in a volumetric flask. Add about 160ml of diluent and 10 ml volumetric flask, adds 1 ml of 1 N NaOH, sonicate for 15 min. Dilute to volume with diluent and heated at 700C for 1 h on a water bath. The and mix. Transfer 4ml of the solution into 250ml flask was removed from the water bath and volumetric flask dilute with diluent and mix. Filt"
Paper-6,Paper-6,TEXT,thermal,50°C,50°C,,,,,"cepts may be used decomposition studies on pharmaceutical to calculate the number of degradants substances and products. Temperature produced (15). (>50°C), humidity (75 percent relative ICH Q3A (impurities in new drug humidity), oxidation, photodegradation, substances): The ICH Q3A guidelines and a wide pH range (solution/suspension) give information on determining were among the factors consider"
Paper-6,Paper-6,CAMELOT_TABLE,thermal,50°C,50°C,,,,,"cepts may be used decomposition studies on pharmaceutical to calculate the number of degradants substances and products. Temperature produced (15). (>50°C), humidity (75 percent relative ICH Q3A (impurities in new drug humidity), oxidation, photodegradation, substances): The ICH Q3A guidelines and a wide pH range (solution/suspension) give information on determining were among the factors consider"
Paper-7,Paper-7,TEXT,thermal,30°C,30°C,80.0 min,,,,"atio as solvent B. The flow rate 1.0 mL/min was selected to achieve the separation of all the peaks and the column oven temperature was maintained at 30°C. Coelution of adapalene impurity D and the blank peak was observed at the retention time of about 80.0 minutes and adapalene peak tailing was observed. Good chromatography was achieved using the mixture of acidic water and acetonitrile (80:20, v"
Paper-7,Paper-7,TEXT,acid_hydrolysis,1 N HCl,,15 min,,,,"ng. Basic degradation was carried out by adding 0.5 mL of 1 N NaOH at room temperature for 15 minutes, then neutralizing the mixture by adding 0.5 mL 1 N HCl. The flask was made up to the volume with diluent and mixed well. The drug was found to be unstable under the above-mentioned degradation conditions. The major impurity in the study was found to be BA (5.7%) with 1.17% as the maximum unknown "
Paper-7,Paper-7,TEXT,base_hydrolysis,1 N NaOH,,15 min,,,,"etric flask, then 10 mL of diluent was added, and it was sonicated for 15 minutes with shaking. Basic degradation was carried out by adding 0.5 mL of 1 N NaOH at room temperature for 15 minutes, then neutralizing the mixture by adding 0.5 mL 1 N HCl. The flask was made up to the volume with diluent and mixed well. The drug was found to be unstable under the above-mentioned degradation conditions. "
Paper-7,Paper-7,TEXT,acid_hydrolysis,1 N HCl,60°C,15 min,,,,"metric flask, then 10 mL of diluent was added, and it was sonicated for 15 minutes with shaking. Acidic degradation was carried out by adding 1 mL of 1 N HCl at 60°C in a water bath, and after 10 minutes the flask was removed and the mixture was neutralized by adding 1 mL 1 N NaOH. The flask was made up to the volume with diluent and mixed well. The drug was found to be unstable under the above-me"
Paper-7,Paper-7,TEXT,base_hydrolysis,1 N NaOH,60°C,10 min,,,,"ried out by adding 1 mL of 1 N HCl at 60°C in a water bath, and after 10 minutes the flask was removed and the mixture was neutralized by adding 1 mL 1 N NaOH. The flask was made up to the volume with diluent and mixed well. The drug was found to be unstable under the above-mentioned degradation conditions. The major impurity in the study was found to be BA (11.4%) with 0.44% as the maximum unknow"
Paper-7,Paper-7,TEXT,oxidation,30% hydrogen peroxide,60°C,15 min,,,,"ric flask, then 10 mL of diluent was added, and it was sonicated for 15 minutes with shaking. Oxidative degradation was carried out by adding 1 mL of 30% hydrogen peroxide at 60°C in a water bath, and after 10 minutes the flask was removed, and the flask was made up to the volume with diluent and mixed well. The drug was found to be unstable under the above-mentioned degradation conditions. The ma"
Paper-7,Paper-7,TEXT,humidity,92% relative humidity,25°C,,92% relative humidity,,,adant at an RRT of about 0.93 and total impurities of about 2.13% (Figure 3). Humidity Degradation The gel sample and placebo samples were exposed to 92% relative humidity (RH) at 25°C. The major impurity in the study was found to be BA (0.95%) with no major unknown degradant observed (Figure 3). The percentage degradation for both components is presented in Table 3(a) and the peak purity results 
Paper-7,Paper-7,TEXT,photolysis,1.2 million lux,25°C,240 h,,1.2 million lux,,(Figure 3). Photolytic Degradation The gel sample and placebo samples were exposed to visible light for 240 h resulting in an overall illustration of 1.2 million lux h; and UV light for 250 h resulting in an overall illustration of 200 w h/m2 at 25°C. The major impurity in the study was found to be BA (1.6%) with 0.5% as the maximum unknown degradant at an RRT of about 0.93 and total impurities of
Paper-7,Paper-7,TEXT,thermal,60°C,60°C,15 min,,,,"k, then 10 mL of diluent was added, and it was sonicated for 15 minutes with shaking. Acidic degradation was carried out by adding 1 mL of 1 N HCl at 60°C in a water bath, and after 10 minutes the flask was removed and the mixture was neutralized by adding 1 mL 1 N NaOH. The flask was made up to the volume with diluent and mixed well. The drug was found to be unstable under the above-mentioned deg"
Paper-7,Paper-7,TEXT,thermal,60°C,60°C,15 min,,,,"diluent was added, and it was sonicated for 15 minutes with shaking. Oxidative degradation was carried out by adding 1 mL of 30% hydrogen peroxide at 60°C in a water bath, and after 10 minutes the flask was removed, and the flask was made up to the volume with diluent and mixed well. The drug was found to be unstable under the above-mentioned degradation conditions. The major impurity in the study"
Paper-7,Paper-7,TEXT,thermal,85°C,85°C,6 h,,,, about 0.78 and total impurities of about 8.94% (Figure 3). Thermal Degradation The formulation sample and placebo sample were exposed to dry heat at 85°C for 6 h. The major impurity in the study was found to be BA (2.13%) with 0.04% as the maximum unknown degradant at an RRT of about 0.78 and total impurities of about 2.24% (Figure 3). Photolytic Degradation The gel sample and placebo samples wer
Paper-7,Paper-7,TEXT,thermal,25°C,25°C,240 h,,1.2 million lux,,ght for 240 h resulting in an overall illustration of 1.2 million lux h; and UV light for 250 h resulting in an overall illustration of 200 w h/m2 at 25°C. The major impurity in the study was found to be BA (1.6%) with 0.5% as the maximum unknown degradant at an RRT of about 0.93 and total impurities of about 2.13% (Figure 3). Humidity Degradation The gel sample and placebo samples were exposed to
Paper-7,Paper-7,TEXT,thermal,25°C,25°C,,92% relative humidity,,,and total impurities of about 2.13% (Figure 3). Humidity Degradation The gel sample and placebo samples were exposed to 92% relative humidity (RH) at 25°C. The major impurity in the study was found to be BA (0.95%) with no major unknown degradant observed (Figure 3). The percentage degradation for both components is presented in Table 3(a) and the peak purity results are presented in Table 3b. Sci
Paper-7,Paper-7,CAMELOT_TABLE,thermal,30°C,30°C,80.0 min,,,,"atio as solvent B. The flow rate 1.0 mL/min was selected to achieve the separation of all the peaks and the column oven temperature was maintained at 30°C. Coelution of adapalene impurity D and the blank peak was observed at the retention time of about 80.0 minutes and adapalene peak tailing was observed. Good chromatography was achieved using the mixture of acidic water and acetonitrile (80:20, v"
Paper-8,Paper-8,TEXT,acid_hydrolysis,0.1 N HCl,,,,,,"pe II (paddle) apparatus (Labindia DS 8000). Each vessel con- bile phase composition (ethanol-to-aqueous formic acid ratio) and flow tained 900 mL of 0.1 N HCl (pH 1.2) maintained at 37 ± 0.5 ◦C, rate, were systematically varied within a defined design space. The representative of gastric conditions, with the paddle rotation speed set at objective was to optimize critical performance characteristi"
Paper-8,Paper-8,TEXT,base_hydrolysis,1 N NaOH,,1 h,,,,ydrolytic degradation was assessed by treating samples with 1 The Hansen Solubility Parameter–based evaluation was conducted using N HCl (acidic) and 1 N NaOH (alkaline) at 60 ◦C for 1 h. Oxidative and the Green Solvent Selection Tool (OPEG). The tool calculates the 3
Paper-8,Paper-8,CAMELOT_TABLE,acid_hydrolysis,0.1 N HCl,,,,,," II (paddle) apparatus (Labindia DS 8000). Each vessel con- bile phase composition (ethanol-to-aqueous formic acid ratio) and flow ◦ tained 900 mL of 0.1 N HCl (pH 1.2) maintained at 37 ± 0.5 C, rate, were systematically varied within a defined design space. The representative of gastric conditions, with the paddle rotation speed set at objective was to optimize critical performance characteristic"
Paper-8,Paper-8,CAMELOT_TABLE,base_hydrolysis,1 N NaOH,,1 h,,,, Hydrolytic degradation was assessed by treating samples with 1 ◦ the Green Solvent Selection Tool (OPEG). The tool calculates the N HCl (acidic) and 1 N NaOH (alkaline) at 60 C for 1 h. Oxidative and
Paper-9,Paper-9,TEXT,thermal,8°C,8°C,,,,,"J.EmanuelliandE.EvaSchermanSchapoval Microchemical Journal 157 (2020) 105084 degradations products formed under extreme conditions, to study the 2–8°Cprotectedfromlightanddilutedwithmobilephasesolutionfor oxidative and photolytic degradation kinetics and to identify the de- thetests. gradation products obtained by the oxidative route proposing a de- gradationpathway. 2.4. Validation 2. Experime"
Paper-9,Paper-9,TEXT,thermal,25°C,25°C,30 min,,,,"or sodium analyticalcolumn(250mm×4.6mm×5µm)(USA).Thesystemwas hydroxide (NaOH) 0.5 M (pH 13.62) was used for hydrolysis. After operatedisocraticallyat25°Cinthecolumnoven,usingamobile-phase 30 min for basic degradation and 24 h for acidic degradation, the composed by 10 µM monobasic potassium phosphate buffer and me- degraded sample solutions were then quantitatively transferred into thanol(45:55v/"
Paper-9,Paper-9,TEXT,thermal,60 °C,60 °C,24 h,,,,"or thermal degradation, the sample solution (1 mg/mL) was (50 × 2.1 mm, 1.8 µm), the mobile phase consisted of water con- exposed to a temperature of 60 °C for 24 h. Then, this solution was taining0.1%phosphoricacidandmethanol(90:10v/v)ataflowrate diluted with mobile phase for the final theoretical concentration of of0.3mL/min.Thedetectionwasdoneat230nm.Dataacquisition 100μg/mLandanalyzedbyHPLC. a"
Paper-9,Paper-9,TEXT,thermal,8°C,8°C,,,,,"standardsolutionof80μg/mLwaspreparedbyproperdilution Methodaccuracywasevaluatedbytherecoveryofknownamounts withamobilephasesolution.Bothwerestoredat2–8°Cprotectedfrom of the OMG reference standard added to the samples at the low, light. mediumandhighlevelsofthenominaldrugconcentration(80µg/mL). Thesolutionwaspreparedintriplicateandtheresultswereexpressed 2.3.2. Samplesolution asthepercentageofOMGr"
Paper-9,Paper-9,TEXT,thermal,26 °C,26 °C,,,,,"evolumewasthencompletedwith tionsonsomeparameterssuchastemperatureofthecolumn(24and methanol and filtered through a 0.45 µm membrane filter. The con- 26 °C), flow (0.7 and 0.9 mL/min) and percentage of organic solvent centrationof1mg/mLmethanolicstocksolutionobtainedwasstoredat (54 and 56%) in a Plackett-Burman design (N = 12). Two injections 2"
Paper-9,Paper-9,TEXT,thermal,25°C,25°C,4min,,,,"nditions selected were the analytical column about4min.Theblacksolutionwasusedtoexcludethepossibilityof ZORBAXEclipseC8(4.6×250mm–particlesize5–µm),at25°C, additionalhydrogenperoxidepeaks. using isocratic mobile phase consisted of methanol and monobasic Regarding thermal (Fig. 1e) and photolytic UV-A (Fig. 1f) de- phosphate buffer 10 µM (55:45) at pH 7.0, run at the flow rate of gradation,noadditi"
Paper-9,Paper-9,TEXT,oxidation,10% hydrogen peroxide,,,,,,"019). The m/z 321 product obtained from the oxidative degradation of [4] T.Biftu,Omarigliptin(MARIZEV®,MK-3102),SuccessfulDrugDiscovery3(2018) OMG in 10% hydrogen peroxide occurs due to breakage of the sulfo- 291–317,https://doi.org/10.1002/9783527808694.ch10. [5] D.J.Drucker,M.A.Nauck,Theincretinsystem:glucagon-likepeptide-1receptor namide bond. This group is very susceptible to this type of reac"
Paper-9,Paper-9,TEXT,thermal,25°C,25°C,,,,,"gent.TheN-oxidationofaminesisveryfavorablein weeklydipeptidylpeptidase-4(DPP-4)inhibitor,aftersingleandmultipledosesin thepresenceofhydrogenperoxideat25°C[29],duetothedirectin- healthysubjects,J.Clin.Pharmacol.56(12)(2016)1528–1537,https://doi.org/ teractionofthesecompoundscausingthetransferofelectronfromthe 10.1002/jcph.773. [10] M.F.Li,X.X.Hu,A.Q.Ma,Ultra-highpressureliquidchromatography–tandemm"
Paper-9,Paper-9,CAMELOT_TABLE,thermal,8 °C,8 °C,,,,,"Emanuelli and E. Eva Scherman Schapoval Microchemical Journal 157 (2020) 105084 degradations products formed under extreme conditions, to study the 2–8 °C protected from light and diluted with mobile phase solution for oxidative and photolytic degradation kinetics and to identify the de- the tests. gradation products obtained by the oxidative route proposing a de- gradation pathway. 2.4. Validatio"
Paper-9,Paper-9,CAMELOT_TABLE,thermal,25 °C,25 °C,30 min,,,,"ical column (250 mm × 4.6 mm × 5 µm) (USA). The system was hydroxide (NaOH) 0.5 M (pH 13.62) was used for hydrolysis. After operated isocratically at 25 °C in the column oven, using a mobile-phase 30 min for basic degradation and 24 h for acidic degradation, the composed by 10 µM monobasic potassium phosphate buffer and me- degraded sample solutions were then quantitatively transferred into thanol"
Paper-9,Paper-9,CAMELOT_TABLE,thermal,60 °C,60 °C,24 h,,,,"or thermal degradation, the sample solution (1 mg/mL) was (50 × 2.1 mm, 1.8 µm), the mobile phase consisted of water con- exposed to a temperature of 60 °C for 24 h. Then, this solution was taining 0.1% phosphoric acid and methanol (90:10 v/v) at a flow rate diluted with mobile phase for the final theoretical concentration of of 0.3 mL/min. The detection was done at 230 nm. Data acquisition 100 μg"
Paper-9,Paper-9,CAMELOT_TABLE,thermal,8 °C,8 °C,,,,,"mL was prepared by proper dilution Method accuracy was evaluated by the recovery of known amounts with a mobile phase solution. Both were stored at 2–8 °C protected from of the OMG reference standard added to the samples at the low, light. medium and high levels of the nominal drug concentration (80 µg/mL). The solution was prepared in triplicate and the results were expressed 2.3.2. Sample soluti"
Paper-9,Paper-9,CAMELOT_TABLE,thermal,26 °C,26 °C,,,,,"n completed with tions on some parameters such as temperature of the column (24 and methanol and filtered through a 0.45 µm membrane filter. The con- 26 °C), flow (0.7 and 0.9 mL/min) and percentage of organic solvent centration of 1 mg/mL methanolic stock solution obtained was stored at (54 and 56%) in a Plackett-Burman design (N = 12). Two injections"
